254435-95-5
254435-95-5 結(jié)構(gòu)式
基本信息
Debio-025
Trofinetide
alisporivir
Alisporivir (Debio-025)
alisporivir /DB025/DB-025
物理化學性質(zhì)
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2026/06/05 | HY-12559 | 254435-95-5 Alisporivir | 254435-95-5 | 1mg | 1200元 |
| 2026/06/05 | HY-12559 | 254435-95-5 Alisporivir | 254435-95-5 | 5mg | 3600元 |
| 2026/06/05 | HY-12559 | 254435-95-5 Alisporivir | 254435-95-5 | 10 mg | 5800元 |
常見問題列表
DEB025 binds to CypA, a peptidyl-prolyl cis-trans isomerase which is a crucial cofactor for HCV replication. Alisporivir (Debio-025) represents the prototype of a new class of non-immunosuppressive cyclophilin inhibitors. Alisporivir prevents HCV protein-mediated collapse of the respiration-driven mitochondrial membrane potential. Alisporivir prevents HCV protein-mediated mitochondrial dysfunction outside the context of apoptosis, calcium overload, production of ROS, dysfunction. In cell culture models, low-micromolar doses of alisporivir block SARS-CoV and MERS-CoV replication. Combination treatment with Alisporivir and ICN-1229 increases the anti-MERS-CoV activity in cell culture. Alisporivir pretreatment stimulates antigen presentation by hepatoma target cells, leading to enhancement of antigen-specific CD8+ T cell activation by 40%. Alisporivir induces an increase of MHC-I and beta-2 microglobulin on the surface of several cell lines.
Combination treatment with Alisporivir and ICN-1229 does not protect against SARS-CoV infection in a mouse model.